- Fractyl Health Announces Multiple Presentations at the Upcoming Digestive Disease Week (DDW) 2024 Conference and the German Diabetes Association (DDG) Annual Meeting
- Fractyl Health Expands Leadership with Appointment of Adrian Kimber as Chief Commercial Officer to Spearhead Anticipated Launch Preparation as the Company Conducts Two Pivotal Studies for Revita in Obesity and Type 2 Diabetes
- Fractyl Health Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
- Fractyl Health Receives FDA IDE Approval for the Revita® Remain-1 Pivotal Study of Weight Maintenance in Obesity after Discontinuation of GLP-1 Based Drugs
- UPDATE -- Fractyl Health Announces New Results From Its Rejuva® Platform Demonstrating Potent and Durable Effects of a Single Dose of a Human GLP-1 Pancreatic Gene Therapy Transgene Compared to Semaglutide in the db/db Mouse Model of Diabetes and Obesity
- Fractyl Health Appoints Samuel Conaway to Its Board of Directors, Bolstering New Product Commercial Expertise During Revita® Pivotal Clinical Trials
More ▼
Key statistics
On Friday, Fractyl Health Inc (GUTS:NMQ) closed at 6.51, 13.22% above the 52 week low of 5.75 set on Apr 01, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.69 |
---|---|
High | 6.69 |
Low | 6.50 |
Bid | 6.11 |
Offer | 6.75 |
Previous close | 6.51 |
Average volume | 131.31k |
---|---|
Shares outstanding | 47.88m |
Free float | 45.83m |
P/E (TTM) | -- |
Market cap | 311.69m USD |
EPS (TTM) | -1.97 USD |
Data delayed at least 15 minutes, as of May 03 2024 21:00 BST.
More ▼